Company Encyclopedia
View More
name
ImmunityBio
IBRX.US
ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company’s platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors.
1.875 T
IBRX.USMarket value -Rank by Market Cap -/-

Financial Score

21/11/2025 Update
C
BiotechnologyIndustry
Industry Ranking85/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE54.92%A
    • Profit Margin-422.28%E
    • Gross Margin99.45%A
  • Growth ScoreA
    • Revenue YoY1025.95%A
    • Net Profit YoY40.69%B
    • Total Assets YoY42.36%A
    • Net Assets YoY29.66%A
  • Cash ScoreB
    • Cash Flow Margin-23.68%D
    • OCF YoY1025.95%A
  • Operating ScoreD
    • Turnover0.19D
  • Debt ScoreE
    • Gearing Ratio200.85%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    ImmunityBio Reports Revenue Surge Amid Financial Challenges

    ImmunityBio Inc (IBRX) reported a significant revenue increase in its Q3 earnings, with total revenue reaching $75 million for the nine months ending September 30, 2025, up from $7.2 million in the same period of 2024. This growth is attributed to the commercial distribution of its FDA-approved product, ANKTIV A, for non-muscle invasive bladder cancer. However, the company faces financial challenges, reporting a net loss of $289.5 million and high operating expenses of $147.1 million in R&D. Management remains optimistic about future growth and is exploring additional financing options.

    Tip Ranks·
    US
    IBRX
    +1.73%
    Tip Ranks·
    US
    IBRX
    +1.73%

    ImmunityBio | 8-K: FY2025 Q3 Revenue Beats Estimate at USD 32.06 M

    LB filings·
    US
    IBRX
    +1.73%
    LB filings·
    US
    IBRX
    +1.73%

    ImmunityBio | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 32.06 M

    LB filings·
    US
    IBRX
    +1.73%
    LB filings·
    US
    IBRX
    +1.73%

    ImmunityBio Q3 revenue jumps on ANKTIVA demand

    ImmunityBio reported a 434% year-over-year increase in Q3 2025 product revenue, driven by strong demand for ANKTIVA. The company's cash position rose to $257.8 million as of September 30, 2025. However, it did not provide specific financial guidance for future quarters. R&D expenses increased to $51.2 million. The average analyst rating is "buy," with a median 12-month price target of $8.00, significantly above its recent closing price of $2.08.

    Reuters·
    US
    IBRX
    +1.73%
    Reuters·
    US
    IBRX
    +1.73%

    ImmunityBio reports $75 million in year-to-date sales and narrows net loss for Q3 2025

    ImmunityBio Inc. reported a significant increase in product revenue, reaching $31.8 million in Q3 2025, up 434% from $6.0 million in Q3 2024. Year-to-date sales totaled $74.7 million, a 467% increase in unit volume compared to the same period last year. The net loss for Q3 2025 was $67.3 million, improved from $85.7 million in Q3 2024. For the first nine months of 2025, the net loss was $289.5 million, down from $354.4 million in 2024. As of September 30, 2025, the company had $257.8 million in cash and equivalents.

    Reuters·
    US
    IBRX
    +1.73%
    Reuters·
    US
    IBRX
    +1.73%